Mometasone Furoate Market Trends

  • Report ID: 5507
  • Published Date: May 07, 2024
  • Report Format: PDF, PPT

Mometasone Furoate Market Trends

Growth Drivers

  • Growing interest in research and development activities - The rising mometasone furoate-related research and development efforts are anticipated to propel mometasone furoate market expansion. According to a report in 2021, one of the most important components of treatment for patients with eosinophilic esophagitis is topical corticosteroids.

    In addition, the purpose of this study was to examine the benefit of utilizing mometasone furoate spray versus placebo on dysphagia and health-related quality of life in these patients.
  • Surge in new product launches - In 2020, Enerzair Breezhaler (QVM149; indacaterol acetate, glycopyrronium bromide, and mometasone furoate [IND/GLY/MF]) was approved by the European Commission (EC) to treat adult patients with asthma who have not had their asthma adequately controlled with a maintenance regimen that includes a long-acting beta2 agonist (LABA) and a high-dose inhaled corticosteroid (ICS) and who have had one or more asthma exacerbations in the preceding year.
  • Rising cases of respiratory allergies - Respiratory allergies can be caused by many irritants, like smoke and fumes, in both indoor and outdoor environments, which can fuel allergy symptoms or several allergic reactions.

    In the immune system, mometasone lessens the appearance of redness, swelling, and itching, which are signs of allergic reactions and inflammatory diseases. The patient’s nose's puffiness and mucous are reduced with the nasal spray. Although the effects last longer than those of antihistamine sprays, it may take a little longer to start working. Therefore, the growing prevalence of respiratory allergies globally is also accelerating mometasone furoate market share.

Challenges

  • Exposure to piracy and corruption - The sector faces a serious threat from some of the common side effects of mometasone, such as allergic reactions, nausea, vomiting, loss of appetite, headaches, and many more. On the other hand, some severe side effects that may negatively impact the growth of the revenue share are crusting, blurry vision or vision loss, and white patches in the nose or mouth. These problems cause barriers for the users, which slows down the mometasone furoate market share.
  • High competition from alternative drugs may hamper the growth of the landscape.
  • The market revenue for mometasone furoate is further hampered by strict regulatory requirements and approval processes.

Mometasone Furoate Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

7%

Base Year Market Size (2023)

USD 1 Billion

Forecast Year Market Size (2036)

USD 3 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Rajrani Baghel


  • Report ID: 5507
  • Published Date: May 07, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2023, the industry size of the mometasone furoate market was over USD 1 billion.

The market size for the mometasone furoate market is projected to cross USD 3 billion by the end of 2036 expanding at a CAGR of 7% during the forecast period i.e., between 2024 and 2036.

The major players in the market are Bausch Health Companies Inc., Glenmark Pharmaceuticals Limited, Vetoquinol USA, AstraZeneca plc, Intersect ENT, Hikma Pharmaceuticals, Medlab Pharmaceuticals Private Limited, AdvaCare Pharma, Dermocare Laboratories, Taro Pharmaceutical Industries Ltd., Kyorin Remedio Co., Ltd, Teikoku Seiyaku Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals., and others.

In terms of route of administration, the topical segment is anticipated to account for the largest market share of 42% during 2024-2036.

The North American mometasone furoate market is poised to hold the highest share of 47% by 2036.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample